All Posts

Over the last several months, the OmicXHealth team conducted a series of structured interviews with hepatologists, gastroenterologists, oncologists, and clinical researchers as part of the regional NSF I-Corps program through UC Berkeley. Our goal was simple: to understand clinical decision making around liver cancer screening and uncover where current approaches fall short. These conversations provided critical insight into how early detection works today and where innovatio

We’re excited to share promising early results from our collaboration with Zymo Research Corp., marking a key milestone in our journey to develop a highly accurate, affordable blood test for liver cancer detection. In this initial evaluation, Zymo sequenced a small set of 12 biobank blood samples, consisting of both early-stage liver cancer and non-cancer liver disease cases. These samples were then analyzed using OmicXHealth’s proprietary AI/ML methylation models. The outcom

After four months of pitching, refining, and learning, OmicXHealth wrapped up the SCU Bronco Ventures Accelerator (BVA7) with an incredible win at Demo Day. It was an inspiring finale to a deeply transformative journey. Participating in the BVA7 program at Santa Clara University has been both energizing and humbling. Over the course of the accelerator, we refined our vision for OmicXHealth, building an AI-powered cfDNA methylation platform for early cancer detection. With gui

AI is no longer on the sidelines of healthcare. It is officially mainstream. At this year’s MedTech Conference in San Diego, artificial intelligence took center stage. Nearly every keynote and workshop explored how AI can streamline change management, improve documentation, and strengthen supply chains across life sciences. Yet even with all the excitement, many conversations still described AI as a supporting player, a helpful tool that enhances existing processes rather tha

We’re excited to share that OmicXHealth has been selected to join the 2025 Bronco Ventures Accelerator (BVA7) at Santa Clara University! This marks another major milestone in our journey. Over the past year, we’ve built a clinically validated, patent-pending platform for early cancer detection using AI/ML models trained on cfDNA methylation data. With the support of Bronco Ventures, we’re now entering the next phase: preparing for clinical launch and scaling our solution to r